KEAP1 and non-small cell lung carcinoma: More KEAP1 mutations were also present in CS1 and CS4; studies have shown that non-small cell lung cancer (NSCLC) patients carrying STK11/KEAP1 mutations have less immune cell infiltration, which may lead to a poorer response to immune checkpoint inhibitors (ICIs) or poorer survival.